Piramal Pharma Ltd (PIRM)

Currency in INR
190.07
-1.78(-0.93%)
Closed·

PIRM Financial Summary

Key Ratios

P/E Ratio280.55
Price/Book3.35
Debt / Equity59.77%
Return on Equity1.14%
Dividend Yield0.07%
EBITDA13.71B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of INR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.74%
Dividend Yield
0.07%
Industry Median 0.73%
Annualised payout
0.14
Paid annually
5-Years Growth
-
Growth Streak

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 256.67
(+35.04% Upside)

Earnings

Latest Release
Jul 28, 2025
EPS / Forecast
-0.80 / -0.6725
Revenue / Forecast
19.34B / 20.12B
EPS Revisions
Last 90 days

FAQ

What were Piramal Pharma's earnings for the latest quarter?

The Piramal Pharma EPS (TTM) is 0.74. Piramal Pharma reported sales of 19,337.10, net income of -817.00, and EPS of -0.80 for the latest quarter.

What was Piramal Pharma's net income for the latest quarter?

Piramal Pharma's net income for the latest quarter was -817.00.

How did Piramal Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 27,540.70 in the previous quarter to 19,337.10 in the latest quarter, and net income moved from 1,535.00 to -817.00 compared to the previous quarter.

What is Piramal Pharma's net profit margin on a TTM basis?

Piramal Pharma's trailing twelve months (TTM) net profit margin is 1.00%.

How does Piramal Pharma's debt to equity ratio compare to industry standards?

Piramal Pharma's total debt-to-equity ratio is 59.77%.

What is Piramal Pharma's return on investment on a TTM basis?

Piramal Pharma's trailing twelve months (TTM) return on investment (ROI) is 1.14%.

How has Piramal Pharma's total revenue grown this year?

Piramal Pharma's total revenue was 27,540.70 in the previous quarter and 19,337.10 in the latest quarter.

What is Piramal Pharma's gross margin on a TTM basis?

Piramal Pharma's trailing twelve months (TTM) gross margin is 60.86%.

What was Piramal Pharma's revenue per share for the latest quarter?

Piramal Pharma's revenue per share for the latest quarter was 301.77.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.